Lorrain Daniel S. 4

What Happened
Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics (CTNM), exercised stock options and sold shares on February 19, 2026. He exercised 100 options at $1.01 per share (outlay $101) and sold 100 shares in an open-market transaction at $16.00 per share for gross proceeds of $1,600. The filing also records a 100-share disposition at $0 related to an exercise/conversion of a derivative. The sale was executed under a pre-established 10b5-1 trading plan.

Key Details

• Transaction date: 2026-02-19; Form filed: 2026-02-20 (timely filing).
• Exercise (code M): 100 shares acquired @ $1.01 each (total cost $101).
• Open-market sale (code S): 100 shares disposed @ $16.00 each (total proceeds $1,600).
• Derivative conversion/disposition (code M): 100 shares disposed @ $0 (filing does not elaborate).
• Footnotes: F1 — transactions effected pursuant to a 10b5-1 plan adopted Sept 23, 2025; F2 — the stock options were fully vested and exercisable.
• Shares owned after the transactions: not specified in this Form 4 excerpt (see the full filing for post-transaction holdings).

Context
The filing shows an option exercise and an open-market sale on the same date; insiders sometimes exercise options and then sell shares the same day to cover costs or diversify, but the filing does not detail settlement mechanics. The activity appears routine and was carried out under a pre-set 10b5‑1 plan; the amounts involved here are small (proceeds ~$1,600).